相关实验视频
Updated: Jul 12, 2025
11:53
Cecal Ligation Puncture Procedure
Published on: May 7, 2011
55.0K
德拉科罗丁向CMPK2,减轻炎症:一种新的治疗败血症治疗方法
Wendan Zhang1,2, Honghong Jiang1,2, Pengli Huang1
1Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, P. R. China.
Clinical and translational medicine
|October 20, 2023
概括
研究人员确定了dracorhodin (DP) 作为一种新的CMPK2抑制剂,这是败血症治疗的关键标. 通过调节NLRP3炎症体,DP有效地减少了小鼠的败血症症状,为败血症提供了一个有前途的治疗策略.
科学领域:
- 生物化学 生化学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 败血症仍然是一个重要的医疗挑战,没有有效的药物治疗.
- 在败血症患者中,CMPK2基因表达高,是潜在的治疗标.
- 向CMPK2的抑制剂至关重要,但仍然是败血症治疗的重大障碍.
研究的目的:
- 发现新的CMPK2抑制剂用于败血症治疗.
- 阐明已识别的抑制剂的作用机制.
- 在临床前败血症模型中评估已识别的化合物的治疗潜力.
主要方法:
- 通过RNA测序,在败血症患者中发现了高CMPK2表达.
- 采用一种亲和性质谱法策略,选来自中国草药的CMPK2配体.
- 德拉科罗丁 (DP) 被确定为一种强大的CMPK2抑制剂,K265被确定为抑制的关键残留物.
- 在体内研究中,使用过血症的小鼠模型来评估DP的疗效和机制.
主要成果:
- 德拉科罗丁 (DP) 被确定为CMPK2.2的天然小分子抑制剂.
- 通过通过LPS诱导的CMPK2通路调节NLRP3炎症体,DP显示出抗炎作用.
- 在小鼠模型中,DP显著减轻了败血症,有效性取决于CMPK2的表达.
结论:
- DP是一种有前途的CMPK2抑制剂,具有对败血症的显著治疗潜力.
- 这项研究为开发向性败血症治疗提供了新的框架.
- 基于CMPK2抑制的向药物开发可以改善败血症患者的临床结果.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170